BGNE - Personalis inks deal with Mapkure for BGB-3245 development

Personalis (PSNL) announces a collaboration with MapKure to use a clinical trial assay ((CTA)) based on the Personalis NeXT Platform to support development of BGB-3245 in patients with advanced or refractory solid tumors.MapKure is a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene (BGNE) and SpringWorks Therapeutics (SWTX).As part of the deal, MapKure will be working with Personalis to utilize the NeXT Platform as a confirmatory test for patients enrolled into the company's Phase 1a/1b dose escalation and expansion clinical trial.Personalis shares up nearly 5% post market.

For further details see:

Personalis inks deal with Mapkure for BGB-3245 development